Azitra (AZTR) Change in Accured Expenses (2022 - 2026)
Azitra (AZTR) posted Change in Accured Expenses of $542064.0 for Q1 2026, up 191.28% on a QoQ basis from -$593872.0 in Q4 2025, and up 933.44% year-over-year from $52452.2 in Q1 2025.
Azitra (AZTR) Change in Accured Expenses (2022 - 2026) Analysis & Trends
Azitra's Change in Accured Expenses history runs 5 years deep, the most recent figure standing at $542064.0 for Q1 2026.
- Quarterly Change in Accured Expenses rose 933.44% year-over-year to $542064.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $106785.0 (up 41.4% YoY) and the FY2025 annual result came in at -$500318.0, down 256.01% from the prior year.
- Change in Accured Expenses was $542064.0 for Q1 2026 at Azitra, up from -$593872.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $542064.0 in Q1 2026 and bottomed at -$593872.0 in Q4 2025.
- A 5-year average of $7950.1 and a median of $24845.0 in 2024 frame the typical range for Change in Accured Expenses.
- Annual changes were most pronounced in 2024 — Change in Accured Expenses slumped 5430.88% — and 2026, when it surged 933.44%.
- Azitra's Change in Accured Expenses stood at $422616.0 in 2022, then plunged by 82.26% to $74978.0 in 2023, then sank by 66.86% to $24845.0 in 2024, then plunged by 2490.31% to -$593872.0 in 2025, then surged by 191.28% to $542064.0 in 2026.
- Business Quant data shows AZTR's Change in Accured Expenses at $542064.0 in Q1 2026, -$593872.0 in Q4 2025, and $53122.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Nanobiotix | 1,785.11 Bn | 1,785.05 Bn | - | - |
| 2 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | 931,000.00 |
| 3 | BeOne Medicines | 473.57 Bn | 468.78 Bn | 1.35 Bn | -16.82 Mn |
| 4 | Vertex Pharmaceuticals | 123.78 Bn | 116.54 Bn | 2.59 Bn | 23.10 Mn |
| 5 | Regeneron Pharmaceuticals | 71.73 Bn | 62.98 Bn | 3.31 Bn | 107.70 Mn |
| 6 | Belite Bio | 62.12 Bn | 62.12 Bn | - | - |
| 7 | Argenx Se | 54.64 Bn | 49.45 Bn | 1.41 Bn | - |
| 8 | Alnylam Pharmaceuticals | 38.05 Bn | 35.05 Bn | 959.66 Mn | -176.03 Mn |
| 9 | Revolution Medicines | 36.28 Bn | 36.28 Bn | - | -16.74 Mn |
| 10 | Azitra | 2.03 Mn | 2.03 Mn | - | 542,064.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 542,064.00 |
| Mar 31, 2026 | 542,064.00 |
| Dec 31, 2025 | -593,872.00 |
| Dec 31, 2025 | -593,872.00 |
| Sep 30, 2025 | 53,122.00 |
| Sep 30, 2025 | 53,122.00 |
| Jun 30, 2025 | 105,471.00 |
| Jun 30, 2025 | 105,471.00 |
| Mar 31, 2025 | -65,039.00 |
| Mar 31, 2025 | -65,039.00 |
| Dec 31, 2024 | 24,845.00 |
| Dec 31, 2024 | 24,845.00 |
| Sep 30, 2024 | -326,143.00 |
| Sep 30, 2024 | -326,143.00 |
| Jun 30, 2024 | 441,859.00 |
| Jun 30, 2024 | 441,859.00 |
| Mar 31, 2024 | -281,096.00 |
| Mar 31, 2024 | -281,096.00 |
| Dec 31, 2023 | 74,978.00 |
| Dec 31, 2023 | 74,978.00 |